Articlenpj drug discovery2025
Genetic evidence informs the direction of therapeutic modulation in drug development.
Article in npj drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- Instability of LLM text embeddings for unsupervised dimension reduction of tabular data.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Determining the correct direction of effect (DOE), whether to increase or decrease the activity of a drug target, is essential for therapeutic success. We introduce a framework to predict DOE at gene and gene-disease levels using gene and protein embeddings and genetic associations across the allele frequency spectrum, respectively. Specifically, we predict: (1) DOE-specific druggability for 19,450 protein-coding genes with a macro-averaged area under the receiver operating characteristic curve (AUROC) of 0.95; (2) isolated DOE among 2553 druggable genes with a macro-averaged AUROC of 0.85; and (3) gene-disease-specific DOE for 47,822 gene-disease pairs with a macro-averaged AUROC of 0.59, with performance improving with genetic evidence availability. Our predictions outperform existing approaches, are associated with clinical trial success, and identify novel therapeutic opportunities. We uncover genetic and functional differences between activator and inhibitor targets, allowing DOE inference independent of disease context. This framework represents a valuable tool for target selection and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.